Title of the article

Title of the article

The Vector Production Center CPV of the Laboratory of Genetic Therapy (UMR1089) in Nantes was labeled by the general secretariat for the investment "Industrial integrator in Gene Therapy" of the Grand National Challenge "Biomedicines".

New innovative therapy drugs or ITNs (gene therapy, cell therapy, antibodies, etc.) have recently emerged in the pharmaceutical landscape. However, the large-scale production of these biomedicines remains a real challenge today.

This is why the French State launched in June, a call for expression of interest (AMI) within the framework of the great national challenge “Bioproduction” in order to identify research core facilities called “Industrial integrators”, capable of of development and cutting-edge innovation in the field of bioproduction.

The major challenge for these integrators is to structure the French bioproduction sector by offering expertise in the development of MTI bioproduction processes with a major objective: improve the production yields of these drugs while controlling their costs so that they are accessible to patients while being compatible with our healthcare system.

In conjunction with healthcare manufacturers, this Grand Challenge should help create an environment favorable to the deployment of new production sites for biomedicines for the health of tomorrow. The CPV as well as the 5 other labeled industrial integrators this summer, the General Secretariat for Investment will be articulated hubs at the interface between industrialists in the sector (pharmaceutical industry and Biotechs) and academic laboratories at the origin of technological innovations.

The certification of the CPV is the achievement of more than 20 years of development innovative recombinant viral vectors, bioproduction processes and analytical methods compatible with the production of clinical grade gene therapy drugs. The industrial integrator label will make it possible to strengthen the strong links that already exist with industrial players in the sector in order to enable effective scaling up of bioproduction. This is a unique opportunity to accentuate the innovation momentum already existing within the CPV and the UMR1089 research unit in Nantes in the field of gene therapy.

Contact: Véronique Blouin - veronique.blouin@univ-nantes.fr

CentreProdVectorsVirals